Sanofi's Toujeo can now face-off with Novo's Tresiba in Japan
This article was originally published in Scrip
Executive Summary
Sanofi's Lantus follow-on product Toujeo (insulin glargine), a next-generation insulin, has been approved by the Ministry of Health, Labor and Welfare (MHLW) in Japan, but the product faces tough competition in the region from Novo Nordisk's already marketed Tresiba (degludec).